Needham Reiterates Buy on Cellebrite DI, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Cikos has reiterated a 'Buy' rating on Cellebrite DI (NASDAQ:CLBT) and maintained a $10 price target.
August 30, 2023 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Cikos has reiterated a 'Buy' rating on Cellebrite DI, maintaining a $10 price target.
The reiteration of a 'Buy' rating by a Needham analyst, along with the maintenance of a $10 price target, indicates a positive outlook for Cellebrite DI. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100